Results 221 to 230 of about 36,414,078 (299)

CASTOR1 Regulates Humoral Immune Responses and Contributes to the Pathogenesis of Systemic Lupus Erythematosus

Arthritis &Rheumatology, EarlyView.
Objective CASTOR1 senses arginine and regulates mammalian target of rapamycin complex 1 (mTORC1), a central metabolic signaling molecule. This study aimed to elucidate the roles of CASTOR1 in humoral immune responses. Methods We analyzed human B cell transcriptomes from healthy controls and patients with systemic lupus erythematosus (SLE) via ...
Takeshi Kusuda, Toshihiko Komai, Takahiro Itamiya, Tatsuki Abe, Tomohisa Okamura, Keishi Fujio   +5 more
wiley   +1 more source

Schisandrin B Targets the PPARγ-MAPK Signaling Axis to Ameliorate High-Fat MCD Diet-Induced MASLD in Mice. [PDF]

Pharmaceuticals (Basel)
Feng XY, Gao M, Liu FL, Li MZ, Cui XL, Wang MY, Zhang ZH, Li H, Wang CM, Sun JH.   +9 more
europepmc   +1 more source

Human Monocytic Models Reveal Genotype‐Dependent Inflammatory Programs in VEXAS Syndrome

Arthritis &Rheumatology, EarlyView.
Objective VEXAS syndrome is a severe X‐linked autoinflammatory disorder caused by somatic mutations in ubiquitin‐like modifier activating enzyme 1 (UBA1), with clinical outcomes that vary by UBA1 genotype. We aimed to elucidate genotype‐specific inflammatory programs and identify potential therapeutic targets.
Kana Higashitani, Tatsuma Ban, Yohei Kirino, Go R. Sato, Soichiro Adachi, Yuki Iizuka, Kayo Harita, Ayaka Maeda, Osamu Ohara, Hideaki Nakajima, Tomohiko Tamura   +10 more
wiley   +1 more source

Research progress on the role of IL‑37 in gynecological and obstetrics‑related diseases (Review). [PDF]

Int J Mol Med
Wang H, Arjune R, Gan W, Guo N, Yu N, Xiong T.   +5 more
europepmc   +1 more source

Treatment‐driven peripheral blood transcriptomic remodelling and baseline predictors of ESSDAI and STAR response to B‐cell therapy in Sjögren's disease

Arthritis &Rheumatology, Accepted Article.
Objective To characterise whole‐blood transcriptomic profiles in adults with active Sjögren's disease (SjD) treated with anti‐CD20 or BlyS/BAFF inhibition, identify markers of clinical response, and define inflammatory pathways linked to non‐response. Methods Whole‐blood RNA sequencing was performed at baseline and week‐24 in participants (n=43) from a
Aimen Ibrahim, Junjie Peng, Eileen Tian, Lucia Martin‐Gutierrez, John Casement, Kyle Thompson, Wan‐Fai Ng, André van Maurik, Elizabeth C Jury, Coziana Ciurtin   +9 more
wiley   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: Catalytic receptors. [PDF]

Br J Pharmacol
Alexander SPH, Fabbro D, Peach CJ, Gibb AJ, Kelly E, Mathie AA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Southan C, Davies JA, Beuve A, Brouckaert P, Bryant C, Burnett JC, Farndale RW, Friebe A, Garthwaite J, Hobbs AJ, Jarvis GE, Kilpatrick L, Koesling D, Kuhn M, Leitinger B, MacEwan D, Monie TP, Potter LR, Russwurm M, Schmidt HHHW, Stasch JP, Waldman SA.   +31 more
europepmc   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Immunometabolism in Obesity-Associated Type 2 Diabetes: Molecular Mechanisms and Emerging Therapeutic Targets. [PDF]

Int J Mol Sci
Acierno C, Cavallo M, D'Ardes D, Boccatonda A, Nilo D, Caturano A.   +5 more
europepmc   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Exploring the intricate relationship between IL-1β and IL-18 in the context of osteoarthritis. [PDF]

Front Immunol
Kumari A, Rasool M.
europepmc   +1 more source